{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T17:01:28Z","timestamp":1776358888514,"version":"3.51.2"},"reference-count":21,"publisher":"Wiley","issue":"17","license":[{"start":{"date-parts":[[2009,6,10]],"date-time":"2009-06-10T00:00:00Z","timestamp":1244592000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2009,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>The incidence, dynamics, and management of cytopenias were investigated in patients with chronic myeloid leukemia in chronic phase (CP CML) who received dasatinib therapy after imatinib failure.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>Data were analyzed from 130 patients with CP CML who were treated with dasatinib from November 2003 to March 2006 in phase 1 (n = 22) or phase 2 or 3 (n = 108) studies for the development of grade 2 to 4 cytopenia (according to the National Cancer Institute Common Terminology Criteria [version 3.0]).<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>Grade 2 to 4 neutropenia and\/or thrombocytopenia occurred in 94 (72%) patients during dasatinib therapy and grade 3 to 4 occurred in 67 (52%) patients. Of the 94 patients who developed grade 2 to 4 neutropenia and\/or thrombocytopenia, 64 (68%) also developed at least grade 2 anemia, and 16 (17%) developed grade 3 to 4 anemia. Management of cytopenias included transient dasatinib interruption in 35 (37%) patients, filgrastim in 12 (14%) patients, recombinant erythropoietin in 29 (45%) patients, and interleukin\u201011 in 3 (5%) patients. Factors associated with an increased risk for developing grade 2 to 4 cytopenias were longer time from diagnosis to treatment, prior interferon or imatinib therapy, and a lower white blood cell count at the initiation of dasatinib therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>Hematologic toxicity was frequent during dasatinib therapy in patients with CP CML, particularly at doses &gt;100 mg daily. Treatment interruption and\/or dose reduction as well as growth factor support were found to be safe and efficacious strategies to facilitate the continuous administration of dasatinib. Cancer 2009. \u00a9 2009 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.24432","type":"journal-article","created":{"date-parts":[[2009,6,10]],"date-time":"2009-06-10T10:33:17Z","timestamp":1244629997000},"page":"3935-3943","source":"Crossref","is-referenced-by-count":35,"title":["Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure"],"prefix":"10.1002","volume":"115","author":[{"given":"Alfonso","family":"Quint\u00e1s\u2010Cardama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio Pires","family":"De Souza Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Faderl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Awais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,6,10]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm049486a"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055229"},{"key":"e_1_2_6_4_2","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1182\/blood.V112.11.450.450","article-title":"Dasatinib time to and durability of major and complete cytogenetic response (MCyR and CCyR) in patients with chronic myeloid leukemia in chronic phase (CML\u2010CP)","volume":"112","author":"Baccarani M","year":"2008","journal-title":"Blood."},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20285"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2003.11.003"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20292"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(03)00190-9"},{"key":"e_1_2_6_9_2","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1182\/blood.V91.10.3607","article-title":"A double\u2010blind placebo\u2010controlled trial of granulocyte colony\u2010stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study","volume":"91","author":"Godwin JE","year":"1998","journal-title":"Blood."},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011573"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"issue":"20","key":"e_1_2_6_12_2","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.1200\/jco.2008.26.15_suppl.7009","article-title":"Dasatinib 2\u2010year efficacy in patients with chronic\u2010phase chronic myelogenous leukemia (CML\u2010CP) with resistance or intolerance to imatinib (START\u2010C)","volume":"26","author":"Mauro M","year":"2008","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_6_13_2","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood.V112.11.3225.3225","article-title":"Dasatinib dose\u2010optimization in chronic phase chronic myeloid leukemia (CML\u2010CP): 2\u2010year data from CA180\u2013034 show equivalent long\u2010term efficacy and improved safety with 100 mg once daily dose","volume":"112","author":"Shah N","year":"2008","journal-title":"Blood."},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0596-561"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1099480"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11863"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402996"},{"key":"e_1_2_6_18_2","first-page":"227","article-title":"Granulocyte colony\u2010stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"88","author":"Marin D","year":"2003","journal-title":"Haematologica."},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2257.2006.00772.x"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402869"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-06-026377"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp078101"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.24432","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.24432","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:24:54Z","timestamp":1760268294000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.24432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,10]]},"references-count":21,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["10.1002\/cncr.24432"],"URL":"https:\/\/doi.org\/10.1002\/cncr.24432","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6,10]]}}}